NZ503248A - Solid oral dosage form comprising a combination of metformin and glibenclamide - Google Patents

Solid oral dosage form comprising a combination of metformin and glibenclamide

Info

Publication number
NZ503248A
NZ503248A NZ503248A NZ50324899A NZ503248A NZ 503248 A NZ503248 A NZ 503248A NZ 503248 A NZ503248 A NZ 503248A NZ 50324899 A NZ50324899 A NZ 50324899A NZ 503248 A NZ503248 A NZ 503248A
Authority
NZ
New Zealand
Prior art keywords
glibenclamide
metformin
combination
dosage form
oral dosage
Prior art date
Application number
NZ503248A
Other languages
English (en)
Inventor
Yves Bonhomme
Geoffrey Nicholson
Gillian Cave
Sarah J Nicholson
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ503248(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipha filed Critical Lipha
Publication of NZ503248A publication Critical patent/NZ503248A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ503248A 1998-07-15 1999-07-12 Solid oral dosage form comprising a combination of metformin and glibenclamide NZ503248A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401781A EP0974356B1 (en) 1998-07-15 1998-07-15 Tablets comprising a combination of metformin and glibenclamide
PCT/EP1999/005571 WO2000003742A2 (en) 1998-07-15 1999-07-12 Solid oral dosage form comprising a combination of metformin and glibenclamide

Publications (1)

Publication Number Publication Date
NZ503248A true NZ503248A (en) 2002-09-27

Family

ID=8235441

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503248A NZ503248A (en) 1998-07-15 1999-07-12 Solid oral dosage form comprising a combination of metformin and glibenclamide

Country Status (27)

Country Link
US (2) US6303146B1 (OSRAM)
EP (4) EP0974356B1 (OSRAM)
JP (2) JP2002520371A (OSRAM)
KR (2) KR20040053177A (OSRAM)
CN (2) CN1146427C (OSRAM)
AP (1) AP1450A (OSRAM)
AR (2) AR013052A1 (OSRAM)
AT (1) ATE250418T1 (OSRAM)
AU (2) AU753604B2 (OSRAM)
BR (1) BR9906600A (OSRAM)
CA (1) CA2303537C (OSRAM)
DE (1) DE69818444T2 (OSRAM)
DK (1) DK0974356T3 (OSRAM)
DZ (1) DZ2846A1 (OSRAM)
ES (1) ES2206868T3 (OSRAM)
ID (1) ID25784A (OSRAM)
MA (1) MA24930A1 (OSRAM)
MY (1) MY129552A (OSRAM)
NZ (1) NZ503248A (OSRAM)
OA (1) OA11400A (OSRAM)
PT (1) PT974356E (OSRAM)
RU (2) RU2226396C2 (OSRAM)
SI (1) SI0974356T1 (OSRAM)
TW (2) TWI245632B (OSRAM)
UY (1) UY25611A1 (OSRAM)
WO (1) WO2000003742A2 (OSRAM)
ZA (1) ZA200001159B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
PL199278B1 (pl) * 1999-11-03 2008-09-30 Bristol Myers Squibb Co Zastosowanie metforminy i gliburydu
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2816841B1 (fr) * 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
US7964216B2 (en) * 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
CN1270724C (zh) 2001-07-30 2006-08-23 三菱制药株式会社 餐后高血糖改善剂
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
DE60219963T2 (de) * 2002-01-25 2008-02-07 Laboratorios Silanes, S.A. De C.V. Pharmazeutische zusammensetzung, die zur glukosekontrolle im blut von patienten mit diabetes typ 2 eingesetzt wird
WO2003072089A1 (en) * 2002-02-21 2003-09-04 Biovail Laboratories Inc. Controlled release dosage forms
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
AU2003246791A1 (en) 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
CN1729005A (zh) * 2002-11-15 2006-02-01 兰贝克赛实验室有限公司 含双胍－磺酰脲类组合的药物剂型
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation
TW200507875A (en) * 2003-04-15 2005-03-01 Chugai Pharmaceutical Co Ltd Remedy for diabetes
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
UY29445A1 (es) * 2005-03-30 2006-10-02 Generex Pharm Inc Composiciones para la transmisión transmucosa oral de la metformina
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
WO2008062273A2 (en) * 2006-11-20 2008-05-29 Cadila Pharmaceuticals Limited Solid oral dosage form having antidiabetic drug combination
TWI421102B (zh) 2007-07-19 2014-01-01 Takeda Pharmaceutical 固態製劑
KR20100040937A (ko) 2007-07-26 2010-04-21 암젠 인크 변형된 레시틴-콜레스테롤 아실트랜스퍼라제 효소
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US20130108699A1 (en) * 2010-04-26 2013-05-02 Jose Antonio Matji Tuduri Highly dispersible granulate for the preparation of formulations of high dosage active substances and procedure for obtaining high dosage active substances thereof
RU2451506C1 (ru) 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Комбинация для лечения сахарного диабета и его осложнений
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
CA2859174C (en) * 2011-12-12 2019-03-05 Orbis Biosciences, Inc. Sustained release particle formulations
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
CN105030793A (zh) * 2015-08-25 2015-11-11 瑞阳制药有限公司 二甲双胍格列本脲胶囊及其制备方法
WO2019070109A1 (es) * 2017-10-03 2019-04-11 Infinite Clinical Research International, S.A. De C.V. Triconjugado para el tratamiento de diabetes mellitus
CN115461344B (zh) 2020-04-01 2024-01-12 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
JP2023528726A (ja) 2020-04-01 2023-07-06 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法
KR102484756B1 (ko) * 2020-11-13 2023-01-06 한국생산기술연구원 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362704C (de) * 1921-08-09 1922-11-02 Naamlooze Vennootschap Interna Vorrichtung zum Senken einer Last, insbesondere eines Rettungsbootes
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
IE63463B1 (en) * 1989-02-06 1995-04-19 Zeneca Ltd Phenylsulphone derivatives
GB9016978D0 (en) * 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
EP1787646A3 (en) 1997-06-18 2007-10-03 Smithkline Beecham Plc Novel method of treatment
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition

Also Published As

Publication number Publication date
WO2000003742A2 (en) 2000-01-27
JP2003292443A (ja) 2003-10-15
KR100478347B1 (ko) 2005-03-23
CN1146427C (zh) 2004-04-21
EP1011684A2 (en) 2000-06-28
ATE250418T1 (de) 2003-10-15
KR20040053177A (ko) 2004-06-23
EP2269613A2 (en) 2011-01-05
US6303146B1 (en) 2001-10-16
AU2003261560A1 (en) 2005-05-26
EP1435240A2 (en) 2004-07-07
DK0974356T3 (da) 2003-10-27
CA2303537A1 (en) 2000-01-27
TW200303208A (en) 2003-09-01
DZ2846A1 (fr) 2003-12-01
ID25784A (id) 2000-11-02
RU2286788C2 (ru) 2006-11-10
TW555560B (en) 2003-10-01
EP2269613A3 (en) 2012-10-17
DE69818444D1 (de) 2003-10-30
DE69818444T2 (de) 2004-05-06
PT974356E (pt) 2004-02-27
SI0974356T1 (en) 2003-12-31
CA2303537C (en) 2005-12-06
CN1486698A (zh) 2004-04-07
ZA200001159B (en) 2001-05-31
OA11400A (en) 2004-04-08
MY129552A (en) 2007-04-30
EP0974356A1 (en) 2000-01-26
AU753604B2 (en) 2002-10-24
MA24930A1 (fr) 2000-04-01
ES2206868T3 (es) 2004-05-16
AR065970A2 (es) 2009-07-15
AU5417999A (en) 2000-02-07
USRE38629E1 (en) 2004-10-19
CN1275082A (zh) 2000-11-29
BR9906600A (pt) 2000-07-18
RU2003126257A (ru) 2005-02-27
AP1450A (en) 2005-07-25
EP1435240A3 (en) 2009-08-12
UY25611A1 (es) 2000-08-21
KR20010030603A (ko) 2001-04-16
RU2226396C2 (ru) 2004-04-10
AP2000001757A0 (en) 2000-03-31
AR013052A1 (es) 2000-11-22
WO2000003742A3 (en) 2000-04-20
JP2002520371A (ja) 2002-07-09
TWI245632B (en) 2005-12-21
EP0974356B1 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
NZ503248A (en) Solid oral dosage form comprising a combination of metformin and glibenclamide
MX9602176A (es) Modafinilo teniendo tamaño de particulas definido.
IL106353A0 (en) Unsymmetrical mono-3-nitro-bis-naphthalimides,their preparation and pharmaceutical compositions containing them
EP0661311A3 (en) Fine particles from the combination of film-forming compositions.
DE3265618D1 (en) Prolonged-action multiple-layer tablets
HUP9800792A3 (en) Benzylpiperidines and piperazines, their use and pharmaceutical compositions containing the same
BG98933A (en) Cooled and atomized nabumetone
GB2246514B (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein
PH27246A (en) Psyllium-containing products
MY106371A (en) Oral pharmaceutical compositions in unit dosage form
EP0640350A3 (en) Ceramic particles and their preparation.
IL109275A0 (en) 5-acylamino-1,2,4-thiadiazoles, their preparation and pharmaceutical compositions containing them
IL110809A0 (en) 1,5-diphenyl-3-pyrazolylalkyl-n-hydroxydithiocarbamates and pharmaceutical compositions containing them
NZ208669A (en) Human calcitonin 2, and pharmaceutical compositions
NZ221189A (en) 1,4-benzodiazepines and pharmaceutical compositions
MD970269A (en) Clavulanates
IL111692A0 (en) Quinoxalines and pharmaceutical compositions containing them
NZ219719A (en) Endo-4-amino-5-chloro-2-methoxy-n-cl-azabicyclo -(3,3,1)-non-4-yl)-benzamide and pharmaceutical compositions
IL101482A0 (en) Substituted 2',3'-dideoxy-5-trifluoromethyluridines,and pharmaceutical compositions containing them
IL116504A0 (en) 14, 17-C2-bridged steroids and pharmaceutical compositions containing the same
BR9915172A (pt) Recipiente para alimentos tendo superfìcie resistente a corte.
IL115882A0 (en) Oxazolyl-and thiazolylimidazo-benzo-and thienodiazepines their manufacture and pharmaceutical compositions containing them
IL114161A0 (en) Amido- quinoxalinediones pharmaceutical compositions containing them and their use
IL94658A0 (en) 1,5-diazabicyclodiones and pharmaceutical compositions containing them
SG25394G (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired